Antimicrobial and anti-viral effects of selenium nanoparticles and selenoprotein based strategies : COVID-19 and beyond
© 2023 Elsevier B.V. All rights reserved..
Deficiency of selenium (Se) has been described in a significant number of COVID-19 patients having a higher incidence of mortality, which makes it a pertinent issue to be addressed clinically for effective management of the COVID-19 pandemic. Se nanoparticles (SeNPs) provide a unique option for managing the havoc caused by the COVID-19 pandemic. SeNPs possess promising anti-inflammatory and anti-fibrotic effects by virtue of their nuclear factor kappa-light-chain-stimulator of activated B cells (NFκB), mitogen-activated protein kinase (MAPKs), and transforming growth factor-beta (TGF-β) modulatory activity. In addition, SeNPs possess remarkable immunomodulatory effects, making them a suitable option for supplementation with a much lower risk of toxicity compared to their elemental counterpart. Further, SeNPs have been shown to curtail viral and microbial infections, thus, making it a novel means to halt viral growth. In addition, it can be administered in the form of aerosol spray, direct injection, or infused thin-film transdermal patches to reduce the spread of this highly contagious viral infection. Moreover, a considerable decrease in the expression of selenoprotein along with enhanced expression of IL-6 in COVID-19 suggests a potential association among selenoprotein expression and COVID-19. In this review, we highlight the unique antimicrobial and antiviral properties of SeNPs and the immunomodulatory potential of selenoproteins. We provide the rationale behind their potentially interesting properties and further exploration in the context of microbial and viral infections. Further, the importance of selenoproteins and their role in maintaining a successful immune response along with their association to Se status is summarized.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:86 |
|---|---|
| Enthalten in: |
Journal of drug delivery science and technology - 86(2023) vom: 27. Sept., Seite 104663 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khurana, Amit [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-inflammatory |
|---|
| Anmerkungen: |
Date Revised 01.07.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jddst.2023.104663 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358642639 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358642639 | ||
| 003 | DE-627 | ||
| 005 | 20231226075200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jddst.2023.104663 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM358642639 | ||
| 035 | |a (NLM)37362903 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khurana, Amit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antimicrobial and anti-viral effects of selenium nanoparticles and selenoprotein based strategies |b COVID-19 and beyond |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a Deficiency of selenium (Se) has been described in a significant number of COVID-19 patients having a higher incidence of mortality, which makes it a pertinent issue to be addressed clinically for effective management of the COVID-19 pandemic. Se nanoparticles (SeNPs) provide a unique option for managing the havoc caused by the COVID-19 pandemic. SeNPs possess promising anti-inflammatory and anti-fibrotic effects by virtue of their nuclear factor kappa-light-chain-stimulator of activated B cells (NFκB), mitogen-activated protein kinase (MAPKs), and transforming growth factor-beta (TGF-β) modulatory activity. In addition, SeNPs possess remarkable immunomodulatory effects, making them a suitable option for supplementation with a much lower risk of toxicity compared to their elemental counterpart. Further, SeNPs have been shown to curtail viral and microbial infections, thus, making it a novel means to halt viral growth. In addition, it can be administered in the form of aerosol spray, direct injection, or infused thin-film transdermal patches to reduce the spread of this highly contagious viral infection. Moreover, a considerable decrease in the expression of selenoprotein along with enhanced expression of IL-6 in COVID-19 suggests a potential association among selenoprotein expression and COVID-19. In this review, we highlight the unique antimicrobial and antiviral properties of SeNPs and the immunomodulatory potential of selenoproteins. We provide the rationale behind their potentially interesting properties and further exploration in the context of microbial and viral infections. Further, the importance of selenoproteins and their role in maintaining a successful immune response along with their association to Se status is summarized | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Anti-inflammatory | |
| 650 | 4 | |a Antimicrobial | |
| 650 | 4 | |a Antiviral | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Selenium nanoparticles | |
| 650 | 4 | |a Selenoproteins | |
| 700 | 1 | |a Allawadhi, Prince |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Vishakha |e verfasserin |4 aut | |
| 700 | 1 | |a Khurana, Isha |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Poonam |e verfasserin |4 aut | |
| 700 | 1 | |a Sathua, Kshirod Bihari |e verfasserin |4 aut | |
| 700 | 1 | |a Allwadhi, Sachin |e verfasserin |4 aut | |
| 700 | 1 | |a Banothu, Anil Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Navik, Umashanker |e verfasserin |4 aut | |
| 700 | 1 | |a Bharani, Kala Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of drug delivery science and technology |d 2008 |g 86(2023) vom: 27. Sept., Seite 104663 |w (DE-627)NLM200381695 |x 1773-2247 |7 nnns |
| 773 | 1 | 8 | |g volume:86 |g year:2023 |g day:27 |g month:09 |g pages:104663 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jddst.2023.104663 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 86 |j 2023 |b 27 |c 09 |h 104663 | ||